Stay updated with breaking news from Nasdaq Acrx. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
AcelRx Pharmaceuticals (NASDAQ:ACRX – Free Report) had its price target trimmed by HC Wainwright from $8.00 to $5.00 in a research note issued to investors on Monday, MarketBeat reports. The brokerage currently has a buy rating on the specialty pharmaceutical company’s stock. HC Wainwright also issued estimates for AcelRx Pharmaceuticals’ FY2024 earnings at ($0.75) EPS, […]
AcelRx Pharmaceuticals (NASDAQ:ACRX – Free Report) had its target price trimmed by HC Wainwright from $8.00 to $5.00 in a research report sent to investors on Monday morning, Marketbeat reports. The firm currently has a buy rating on the specialty pharmaceutical company’s stock. HC Wainwright also issued estimates for AcelRx Pharmaceuticals’ FY2024 earnings at ($0.75) […]
AcelRx Pharmaceuticals (NASDAQ:ACRX – Get Free Report) and Cellectar Biosciences (NASDAQ:CLRB – Get Free Report) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, dividends, risk, institutional ownership, valuation, analyst recommendations and earnings. Volatility & Risk AcelRx Pharmaceuticals has a […]
HC Wainwright upgraded shares of AcelRx Pharmaceuticals (NASDAQ:ACRX – Free Report) from a neutral rating to a buy rating in a research report sent to investors on Friday, Marketbeat.com reports. HC Wainwright currently has $8.00 price target on the specialty pharmaceutical company’s stock. HC Wainwright also issued estimates for AcelRx Pharmaceuticals’ Q1 2024 earnings at […]
HC Wainwright upgraded shares of AcelRx Pharmaceuticals (NASDAQ:ACRX – Free Report) from a neutral rating to a buy rating in a report released on Friday, MarketBeat Ratings reports. They currently have $8.00 price objective on the specialty pharmaceutical company’s stock. HC Wainwright also issued estimates for AcelRx Pharmaceuticals’ Q1 2024 earnings at ($0.21) EPS, Q2 […]